Review of the History and Current Status of Cell-Transplant Approaches for the Management of Neuropathic Pain by Eaton, Mary J. et al.
Hindawi Publishing Corporation
Pain Research and Treatment
Volume 2012, Article ID 263972, 22 pages
doi:10.1155/2012/263972
Review Article
Reviewof the History and CurrentStatus of Cell-Transplant
Approaches for the Management of Neuropathic Pain
Mary J. Eaton,1 Yerko Berrocal,2 Stacey Q. Wolfe,3 andEvaWiderstr¨ om-Noga1,4
1Miami VA Health System Center, D806C, 1201 NW 16th Street, Miami, FL 33125, USA
2Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University,
Miami, FL 33199, USA
3Department of Neurosurgery, Tripler Army Medical Center, 1 Jarrett White Road, Honolulu, HI 96859, USA
4The Miami Project to Cure Paralysis, Miller School of Medicine at the University of Miami, Miami, FL 33136, USA
Correspondence should be addressed to Mary J. Eaton, meatonscience@gmail.com
Received 8 March 2012; Accepted 9 April 2012
Academic Editor: Steve McGaraughty
Copyright © 2012 Mary J. Eaton et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Treatment of sensory neuropathies, whether inherited or caused by trauma, the progress of diabetes, or other disease states, are
among the most diﬃcult problems in modern clinical practice. Cell therapy to release antinociceptive agents near the injured
spinal cord would be the logical next step in the development of treatment modalities. But few clinical trials, especially for chronic
pain, have tested the transplant of cells or a cell line to treat human disease. The history of the research and development of useful
cell-transplant-based approaches oﬀers an understanding of the advantages and problems associated with these technologies, but




poses can be envisioned with increasingly demanding goals
in mind: (1) local and sustained provision of therapeutic
molecules, such as pharmacologic agents and neurotrophic
factors; and (2) replacement of lost cellular populations and
reconstruction of local neuronal circuitry. To a large extent,
the demands of the particular therapeutic application will
be the key factor in determining the goals of the transplant
paradigm, and this guides both the selection of optimal cell
type(s) and parameters (graft dose, site, timing, immuno-
suppressive regimen, etc.) for transplantation. With this in
mind, the current review will explore the wide variety of
approachesinneuraltransplantationthathavebeenexplored
for the therapeutic management of pain. Since the goals of
pain management can be widely disparate, approaches have
evolved along distinctive paths during the progression of this
ﬁeld. Thus, while the provision of a local cellular source
of biologic, rather than pharmacologic analgesic molecules
may be appropriate in the management of some etiologies of
new-developing neuropathic pain, cases of chronic, persist-
ent neuropathic might require more heroic measures includ-
ing replacement of lost neural populations and reestab-
lishment of appropriate neurocircuitry. Nevertheless, some
overlap in the goals of these requirements can be envisioned,
for example, the provision of neurotrophic or neuropro-
tective molecules for the attenuation of hyperexcitability in
acutepainorreplacementoflostinhibitoryneurocircuitryin
chronic pain. Thus, this review will examine the history and
development of the various cell types and paradigms, which
run the gamut from primary tissue fragments to engineered
stem cell lines, that have been taken in various models of
chronic pain in order to identify breakthrough approaches
in the treatment of these debilitating conditions.
During the past three decades, cell therapy as an
approach to treat pain has progressed from a hypothesis for
amethodformodulatingpainprocessingtothedevelopment
of the ﬁrst human cell sources that are being tested in clinical
pain treatment. The near future will likely provide new2 Pain Research and Treatment
challenges for the implementation in a wider audience of
those who suﬀer chronic pain, considering problems com-
mon to all forms of cell transplantation, that is, immune
rejection versus long-term survival and eﬃcacy in the
human host; dependable, well-characterized cell sources for
grafts; cells that can safely integrate into or near the CNS,
without danger of tumors or signiﬁcant, deleterious eﬀects;
the ability to control the antinociceptive output of cell grafts,
ideally increasing with the cyclic episodes of pain eﬃcacy
in a wide variety of pain causalities. However, cell therapy
for pain oﬀers much promise as a replacement or adjunct
to current clinical methodologies, once the mechanisms of
pain are well understood, so that such bioengineered cellular
tools can be used appropriately. Although it is likely that the
majority of the cell types grafted thus far are functioning
much like a cellular minipump, providing neuroprotective
and neurotrophic agents in the damaged CNS, more studies
to implement lost neuronal circuitry to modulate pain need
to be accomplished. Future studies will likely better deﬁne
the processes and mechanisms that will lead to improved
selection of cell types and trophic agents which can be uti-
lized in combination to provide improved therapeutic out-
comes following disease and injury to the nervous system
that leads to debilitating pain.
2. Problem of Chronic Neuropathic Pain in
VariousDiseaseStates andPNS/CNS Injuries
Thetreatmentofneuropathicpainisperhapsoneofthemost
diﬃcult problems in modern clinical practice. In addition to
aﬀecting a large population, it is a staggeringly heterogenous
diagnosis with multiple etiologies which respond in varied
manners to a myriad of treatments. Current pharmacologic
treatments often prove ineﬀe c t i v e ,m u s tb eu s e da ti m p r a c t i -
cal dose levels, or have unacceptable side eﬀects.
While the prevalence of neuropathic pain had previously
been conservatively estimated at 0.6% of the U.S. population
[1], better deﬁnition, understanding and recognition of this
diagnosis has led to a more realistic prevalence of 7-8%,
recently reported in Europe [2, 3]. A recent review by the
Neuropathic Pain Special Interest Group of the Interna-
tional Association for the Study of Pain (IASP) estimated
the overall prevalence of neuropathic pain at 3.3 to 8.2%
[4]. However, due to the large variation in reported pre-
valence and incidence, they also recommended further
research eﬀorts regarding the development of standardized
methods for identiﬁcation and assessment of neuropathic
pain. Neuropathic pain usually presents with allodynia, pain
felt in response to a normally innocuous stimulus, and
hyperalgesia, increased sensation of suprathreshold nocicep-
tive stimuli [5]. It is often associated with uncomfortable
dysesthesias and may have continuous and paroxysmal com-
ponents.
3.Etiologies
Neuropathic pain may result from disorders of the central
nervous system, the peripheral nervous system, or may be
mixed. Nearly any traumatic event or disease leading to
neuronal damage, or neuropathy, has the potential to cause
neuropathic pain. Causes of neuropathy include trauma,
vascularandmetabolicdisorders,infections,neoplasms,tox-
ins, autoimmune disease, as well as genetic and nutritional
deﬁciencies. As the individual causes of neuropathic pain
are seemingly innumerable, we will mention only the more
common etiologies.
Trauma,usuallyintheformofspinalcordinjuryandalso
due to direct peripheral nerve damage, is one of the leading
causesofsevereneuropathicpain[6].Traumaticneuropathic
pain aﬀects nearly 60% of individuals with spinal cord injury
[5]. Neuropathic pain is most common at or below the level
ofinjuryandisoftendiﬀuseandpoorlylocalized[7],making
t h i styp eo fp a i nd i ﬃcult to deal with for the individuals with
SCI [8]. Few treatments are eﬀective and most individuals
havetocontinuetoleavewithpersistentpain[9].Whilethere
are several pharmacologic agents that have shown success in
clinical trials [10], the side eﬀects are often ill tolerated at the
dosages needed for relief.
One of the most common peripheral causes of neu-
ropathic pain is diabetes. Diabetes mellitus is one of the
most prevalent diseases in the United States, aﬀecting 25.8
million (8.3% of the population) [11]. Nearly 70 percent
of those with diabetes have diabetic peripheral neuropathy,
which can lead to severe neuropathic pain of the distal
extremities.
There are many infectious causes of peripheral neuropa-
thy, including viral and bacterial etiologies. Viral infections
a r em o r ec o m m o na n du s u a l l yr e s u l ti nm o r es e v e r en e u r o -
pathic pain. They include herpes varicella-zoster (shingles),
Epstein-Barr virus, cytomegalovirus, and herpes simplex.
Thehumanimmunodeﬁciencyvirus(HIV)cancauseseveral
diﬀerent forms of neuropathy, including a rapidly progres-
sive, painful polyneuropathy aﬀecting the distal extremities
which is often the ﬁrst clinically apparent sign of HIV infec-
tion [12]. Lyme disease, diphtheria, and leprosy are bacterial
diseases characterized by extensive peripheral nerve damage.
Neoplasms can create neuropathic pain due to direct nerve
compression and/or inﬁltration. While in a pure sensory
nerve,thesemaybesurgicallyresected;casesinvolvingmotor
nerves or plexi are not amenable to surgical therapy and
must be managed by pharmacologic or neuromodulatory
treatments. Radiation, certain chemotherapeutic agents, and
paraneoplastic syndromes can also result in peripheral neu-
ropathy.
Toxins can result in a heterogeneous group of peripheral
neuropathies. Those exposed to heavy metals, such as arsen-
ic, lead, mercury, thallium, or industrial toxins, as well as
certain therapeutic drugs in the anticonvulsant, chemother-
apeutic, antiviral, and antibiotic classes, can also cause
peripheral neuropathy and neuropathic pain. Nutritional
deﬁciencies, in particular thiamine deﬁciency due to its
prevalence amongst alcoholics, may also result in peripheral
neuropathy. Trigeminal neuralgia is an excruciating cause
of facial pain but is usually amenable to surgical vascular
decompression of the nerve. Central neuropathic pain can
be caused by multiple sclerosis and certain stroke syndromes
[13]. Genetic and autoimmune neuropathies are rarer butPain Research and Treatment 3
add to the overall population of those with neuropathic
pain.
4. Treatment
Given the widely diversiﬁed causes of central and peripheral
neuropathy that can lead to neuropathic pain, it becomes
much clearer as to the diﬃculty in treating this diagnosis.
Clearly, the underlying condition is treated ﬁrst, followed
by symptomatic treatment of the pain. Unfortunately, only
a dismal 40–60% of patients with neuropathic pain achieve
partial relief. A signiﬁcant roadblock of the treatment
dilemma has been the diﬃculty with the most appropriate
animal model to use for basic research, as well as the dis-
connect between behavioral outcomes examined in animal
studies and those reported in the presentation of pain in a
clinical setting [14].
In an eﬀort to clarify the existing therapeutic paradigm
for neuropathic pain, recent guidelines have been derived
for pharmacological therapy [15–18]. These have combined
evidence from randomized controlled trials with expert
opinion and currently oﬀer the clearest treatment paradigm.
While certain drugs work best for speciﬁc indications, likely
due to the mechanism of that disease etiology, it is becoming
clearer that a combination of pharmacologics, adjuvant
treatment and neuromodulation are usually needed to attain
adequate pain relief [19–21].
Despite multiple therapeutic options, the treatment of
neuropathic pain remains diﬃcult and inconsistent. While
combination therapy and an increasing number of adjunct
therapiesassistintreatingintractablepain,therestillremains
no cure. Pain despite standard treatment due to poor eﬃ-
cacy, unacceptable side eﬀects, and disease escalation de-
mandcontinued investigation anddevelopment of newtech-
nologies to treat neuropathic pain.
5. PainClassiﬁcation
In the clinical setting, a broad classiﬁcation of pain is made
inordertodiﬀerentiatebetweennociceptiveandneuropathic
pain types. This is a critical distinction because these pain
types are dependent on partly diﬀerent underlying mecha-
nisms, and therefore, they usually require diﬀerent treatment
strategies.Arrivingatanaccurateneuropathicpaindiagnosis
isnotstraightforward,andthisproblemhasbeenrecognized
both in pain research and in clinical pain management set-
tings. To address this problem, the International Association
for the Study of Pain (IASP) has proposed a modiﬁcation
of the present pain taxonomy. Neuropathic pain is currently
deﬁned as “pain initiated or caused by a primary lesion or
dysfunction in the nervous system” [22]. However, Treede
and colleagues [23, 24] recently suggested eliminating “dys-
function”fromthedeﬁnitionandinsteadredeﬁnetheneuro-
pathicpaindeﬁnitionto“painarisingasadirectconsequence
of a lesion or disease aﬀecting the somatosensory system.”
In order to standardize the classiﬁcation into neuropathic
andnonneuropathicpain,theyrecommendeddiﬀerentiating
pain into “deﬁnite,” “probable,” and “possible” neuropathic
pain. The following criteria were proposed to be required for
“deﬁnite” neuropathic pain: (1) pain distribution consistent
with injury to the peripheral nervous system (PNS) or the
central nervous system (CNS); (2) history of an injury or
diseaseaﬀectingthePNSorCNS;(3)abnormalsensorysigns
within the body area corresponding to the injured area of
the CNS or PNS; (4) a diagnostic test conﬁrming a lesion or
disease in these structures.
These criteria are applicable to many neuropathic pain
conditions. However, in conditions with multiple concomi-
tant pain types after CNS injuries, such as in SCI-related
pain, distinguishing between neuropathic and nociceptive
pain may be more diﬃcult when pain is located in an area
below the lesion but with partial sensory preservation. For
such pain locations, abnormal sensory ﬁndings may not
indicate a neuropathic pain diagnosis, since these will be
present in the painful area regardless of whether pain is
nociceptive or neuropathic [25].
Basicresearchstudieshaveidentiﬁedmultipleunderlying
mechanisms of neuropathic pain and designed interventions
to target them. However, signiﬁcant knowledge gaps exist
regarding the best methods to characterize pain subgroups
(phenotypes) and their relationship to the underlying pain
mechanisms in pain patients. A precise diagnosis is critical
to the development of more eﬀective treatments that are
tailored to speciﬁc underlying mechanisms. Because neuro-
pathic pain is dependent on multiple mechanisms [26], this
knowledge gap is a signiﬁcant barrier to translation of basic
research ﬁnding into successful management of neuropathic
pain.
The determination of clinical pain phenotypes is a pro-
mising way to classify pain types. This process may include
statistical grouping of pain characteristics [27]. For exam-
ple, a combination of the descriptive adjectives “burning,”
“tingling,” “pricking,” “shooting,” and “freezing” pain, and
evoked pain, diﬀerentiated between neuropathic and non-
neuropathic pain in 618 patients with diabetic neuropathic
pain,idiopathic neuropathic pain,orpost-herpetic neuralgia
or nociceptive osteoarthritis pain, or low back pain [28].
Another method used for deﬁning clinical pain phenotypes
includes quantitative sensory testing (QST; [29, 30]). Mea-
surement of detection thresholds for tactile stimuli deter-
mines large-ﬁber and dorsal column-mediated function, and
thermal detection and pain thresholds determine small-ﬁber
and spinothalamic tract-mediated function. Thus, QST may
facilitate the comparisons with basic research studies, since




6.1. Cellular Minipumps for Treatment of Pain. The earliest
studies using cell transplants for pain were originally devel-
oped from the concept of descending inhibitory neuro-
transmitter modulation of sensory information [31], and
that these same agents, such as catecholamines and opiates,
released by cell grafts [32–36] after injury, could provide
antinociception. Projections from midbrain, locus ceru-
leus, ventromedial, and ventrolateral medulla directly or4 Pain Research and Treatment
indirectly terminate at spinal level to modulate incoming
nociceptive signals. In addition, dorsal horn interneurons
provide inhibitory inﬂuences at the same termini. A variety
of neurotransmitters, peptides, opioids, and lately neurotro-
phins, such as BDNF, have been implicated in spinal inhibi-
tion. These include the endogenous neurotransmitters sero-
tonin (5HT), noradrenaline, and gamma-aminobutyric acid
(GABA); the endogenous opioids ß-endorphin, enkephalins,
cannabinoids; endogenous peptides such galanin, and neu-
rotrophins such as BDNF. Many of the commonly used
pharmacologic therapies target these agents’ receptors and
reuptake mechanisms to increase or imitate their presence
in acute and chronic pain. But it was recognized as early
as 1980s [36] that these agents could be supplied by grafts
of autologous adrenal medullary tissue [37] or chromaﬃn
cells [38] which had been puriﬁed from adrenal tissue, and
transplanted in a chronic arthritic pain model [39], after
nervetransection[40],orperipheralnerveinjuryandpainful
neuropathy [41, 42] to attenuate behavioral hypersensitivity.
Where a similar strategy using pharmacological agents
and mechanical intrathecal delivery might be considered,
intrathecal and/or intra administration cerebroventricular of
opioids is limited by cost, the need for specialized main-
tenance and mechanical malfunctions if implantable drug
delivery systems, or by the risk of bacterial contamination
and ambulatory constraints when repeated daily injections
via an intrathecal access port are used [43]. Intrathecal cell
therapy secreting these same antinociceptive agents can be
seen as an advantage. Since it was also noted that minimal
immunosuppression was all that was required for good graft
function and survival in the immune-protected nervous
system [44], such studies led to the early initiation of clini-
cal trials for chronic cancer pain with this cell transplant
approach [42, 45, 46].
7. Early Use of Cell Therapy
7.1. Primary Adrenal ChromaﬃnT i s s u ea n dC e l l s .Some
of the earliest studies utilized primary chromaﬃnc e l l si n
a rat model of neuropathic pain [41]. Chromaﬃnc e l l s
contain a cocktail of antinociceptive agents, peptides, and
neurotrophins [47, 48]. These chromaﬃnc e l lg r a f t sw e r e
placed either in midbrain structures [38], or in the lumbar
subarachnoid space after partial chronic constriction injury
(CCI) to the sciatic nerve [42], or after injection of formalin
in the rat’s hindpaw [49] for the antinociceptive eﬀect. Many
studies have sought to elucidate the agents released by these
chromaﬃn grafts that might serve an antinociceptive role.
These primary chromaﬃn cells grafts raise the levels of CSF
met-enkephalin [32], increase CSF levels of catecholamines
[50], and reduce morphine cross-tolerance [51] when
used with morphine for pain. Changes in the spinal cord
induced by nerve injury are attenuated by chromaﬃn grafts,
such the induction of spinal NADPH-diaphorase [52]a n d
cGMP [53], spinal c-fos induction [54], NMDA-induced
hypersensitivity [55], and the loss of endogenous inhibitory
GABA synthesis in the dorsal horn [56] that accompanies
nerve injury. It is likely that adrenal transplants also block
short-term spinal nociceptive facilitation, illustrated by the
reduction in the c-fos induction by formalin in the presence
of chromaﬃng r a f t s[ 57], probably by stimulating some
persistent cellular process, such as increasing the descending
inhibitory controls that regulate the ﬁring of subpopulations
of spinal cord nociresponsive neurons with release of opioids
from grafted chromaﬃn cells, inhibitory modulation that
may be an important determinant, but not the only one,
of their analgesic eﬀect [58]. To be able to use chromaﬃn
cell therapy in humans, adrenal chromaﬃnc e l lg r a f t sw e r e
prepared from xenogenic bovine sources and tested for
antinociception after nerve injury [35, 59]. Such sources of
primary bovine chromaﬃn cells have been safely used in
initialtrialswithhumanpatientswithintractablecancerpain
[60, 61]. But such primary tissue sources for the puriﬁcation
and use of chromaﬃn cells are not likely to be homogeneous,
since they are often obtained from multiple donors. The
ability to use and manipulate cell lines as a deﬁned and stable
source would be an alternate for eventual use in cell therapy.
Adult human chromaﬃn tissue has also been trans-
planted in humans for cancer pain [62], but when the
immune response in the human host is examined after
human chromaﬃn grafts, one conclusion is that further pur-
iﬁcation and/or the immunoisolation of tissues grafted in
the CNS will be necessary when using these primary adult
human adrenal sources, particularly when the possibility of
long-termandrepeatedgraftingisconsidered[63].However,
there are recent reports [64]o fs u c c e s s f u lh u m a nf e t a l
adrenal transplant to treat pain associated with rheumatoid
arthritis, and in a rat model of partial nerve injury [65],
certainly suggesting that fetal or precursor chromaﬃnt i s s u e
couldbeusedasanantinociceptivesource[66,67].Butusing
such primary tissue sources for the further puriﬁcation [68]
for successful cell therapy necessitates immunosuppression
of the human host, such that examination of encapsulation
technologies of grafted cells continued in many rat and
human studies (Figure 1).
7.2. Clinical Trials Utilizing Cell Therapy for Neuropathic
Pain. As mentioned above, cell therapy utilizing intrathecal
adrenal chromaﬃn grafts to treat cancer pain was initiated
in the early 1990s [41, 46, 61], which reported long-lasting
pain relief, in correlation with met-enkephalin release into
the CSF [43]. Typically not all late-stage cancer patients
respond well to systemic opioids for pain management,
with adverse eﬀects and poor pain control [69], and hence
requiringintrathecaldelivery.Theeﬃcacyofthiscelltherapy
technique depends on the ability of those cells to produce
analgesic opioids and on the immuno-privileged property
of the central nervous system, in which rejection risks are
limited[70].BeforeinclusioninanopenPhaseIItrial,allthe
cancer patients to be grafted with human chromaﬃnc e l l s
had their pain controlled by daily intrathecal (I-Th) mor-
phine administration. Out of the 12 patients who proﬁted
from enhanced analgesia with long-term followup (average
4.5 months), ﬁve no longer required the I-Th morphine
(with prolonged interruption of systemic opioids as well),
two durably decreased I-Th morphine intake, and ﬁve were




Figure 1: Model of lumbar subarachnoid injection of human
neurons near the human spinal cord. MRI image of the human
spinal cord (a) with a lumbar puncture of the subarachnoid
space adjacent to the cord (b), and injection of cells, such as the
GABAergic human neuronal hNT2.17 cells (c) for pain relief, as
delivered by syringe (d). A similar technique has been used in all
pre-clinical animal experiments and clinical studies with human
chromaﬃn cell injections for pain.
stabilization were interpreted as indicative of analgesic activ-
ity by comparison with the usual dose escalation observed
during disease progression, related to increased CSF met-
enkephalin levels associated with the grafts [71]. The grafts
were tolerated, and there is evidence of long-term survival
[72], despite the presence of CSF lymphocytes, where single
treatment failure and three of four cases of partial eﬃcacy
occurred in grafts where CSF lymphocytes were present,
indicating that impairment of the local immunosuppressive
balance can lead to activation of host CSF CD4 T cells and
drive a rejection process when grafts are not encapsulated
[63]. It was concluded that graft immunoisolation, by using
cell encapsulation, seems to be unavoidable in spite of the
graft site [70]. Such ultimately failed clinical trials provided
a better understanding of the limits (at that time) for this
approach[43,62,72,73].Adulthumanchromaﬃntissuehas
also been transplanted in humans for cancer pain [62], but
when the immune response in the human host is examined
after human chromaﬃn grafts, one conclusion is that further
puriﬁcation and/or the immunoisolation of tissues grafted
in the CNS will be necessary when using these primary adult
human adrenal sources, particularly when the possibility of
long-term and repeated grafting is considered [63]. However
there is a recent report [64]o fs u c c e s s f u lh u m a nf e t a la d r e n a l
transplant to treat pain associated with rheumatoid arthritis,
certainly suggesting that fetal or precursor chromaﬃn
tissue could be used as an antinociceptive source [66]. But
such primary tissue sources for the puriﬁcation and use of
chromaﬃn cells are not likely to be homogeneous, since they
are often obtained from multiple donors. The ability to use
and manipulate stable antinociceptive cell lines as a deﬁned
source has provided a rich literature for their experimental
use in cell therapy (Table 1).
8. Strategies for the Creationof Immortalized
CellLines: Rationale/Studies
8.1. Naturally Occurring (Tumor) Cell Lines. A cell line has
the ability to be expanded in vitro, is stable enough in its
p h e n o typ et ob ec h a r a c t e ri z e din vitro and after grafting; and
can be used for in vivo transplant. The archetypal adrenal
medullary cell line is the rat PC12 cell line, ﬁrst established
from a transplantable rat adrenal pheochromocytoma
[74], which was shown to respond to NGF with reversible
loss of mitotic activity and diﬀerentiation to a neuronal
phenotype. This natural, oncogenic cell line has been used
as a model to bioengineer the addition of the gene [75]f o r
the analgesic [76] peptide histogranin (SHG) which acts as
an antagonist for the excitatory NMDA receptor, as SHG can
enhance the antinociceptive properties of grafted cells, such
as chromaﬃn transplants [77]. Although originally reported
to lack phenylethanolamine N-methyltransferase (PNMT)
and epinephrine synthetic capability [74], further character-
ization [78] suggests both PNMT activity and epinephrine
synthesis in PC12 cells. Although this cell line has often been
examined for its response to manipulation to agents, such as
morphine analogs important in pain modulation [79], it has
also been tested as a grafted catecholamine source to test cell
therapyforpainrelief[80].However,PC12cellstendtoform
tumors, rather than to integrate and release antinociceptive
agents. Grafts of the mouse B16 F1C29 melanoma cell line,
which also release catecholamines, was able to reduce pain
behaviors in the tail-ﬂick model when accompanied by
morphine [81], but again, such grafts are tumorigenic, and
their transplant can itself induce pain behaviors [82]. The
monaminergic human NB69 neuroblastoma cell line was
able to reduce neuropathic pain in a nerve injury model
[83], presumably related to serotonin release from the grafts,
but the tumorigenic potential is a consideration with a non-
diﬀerentiated tumor line. Other studies with implantation
of tumor-derived cell lines, like AtT-20 or AtT20/hENK
[84], Neuro2A [85], Neuro2A/POMC [86], or P19 [87], that
overexpress opioid peptides have been attempted, but such
grafts would also carry the risk of tumor formation.
Although the ability of opioids to provide pain relief
withSCIremainscontroversial,thereleaseofenkephalin-like
molecules from genetically modiﬁed cell grafts, such as At-
T20/ENK cells, as therapeutic was an early strategy [84, 88].
One goal of such a opioid-based strategy would be to reduce
the side-eﬀect of tolerance that develops with morphine and
its analogs [84]( Table 2).
8.2. Conditional Immortalization to Create Cell Lines. Retro-
viral infection of neural precursors, when cells are actively
proliferating, with an immortalizing gene sequence in vitro,
is a strategy applicable to a variety of cell types that
might be useful for transplantation [89], and especially the
neural phenotype with v-myc [90] or the wild-type SV406 Pain Research and Treatment
Table 1: Primary tissue used for cell therapy.
Source Pain model Results
Primary cells/tissue:
Adrenal-rat
[49, 57, 58, 219, 245–249]
Bovine












Formalin [54, 58, 247, 249,
253, 260, 261]
Nerve injury






[64, 71, 266, 267]
Arthritis [56, 65, 268]
(i) Reduced “excessive grooming” behaviors [219]
(ii) Reduction or stabilization in complementary opioid intake in human
cancer [71]
(iii) Reductions in both fore- and hindlimb mechanical and thermal allodynia
[245]
(iv) Failed antinociception after intraventricular transplant [256]
(v) Reduces edema, anterograde axoplasmic transport [249]
(vi) Restores spinal GABA-ir decreased spinal c-Fos [58, 253]
(vii) Failed antinociception [247, 247, 269–271]
(viii) Reduced cold or TA/TH behaviors [67, 219, 262]
(ix) Reduced tonic pain behaviors [261]
(x) Delayed, reduced self-directed pain behaviors [246]
(xi) Antinociceptive eﬀects on A-delta and C-ﬁber-mediated responses [59]
(xiii) Long-term proenk and tyrosine hydroxlylase in grafts [248]
(xiv) Reduce forelimb/hindlimb allodynia [245]
Table 2: Naturally occurring (tumor) cell lines.













[81, 84, 85, 87, 88]
Acute [81, 84, 85, 88, 273]
Partial nerve injury (CCI)
[83, 272, 274]
Formalin [87]
(i) Analgesic [85, 88]
(ii) Reduced opioid tolerance [84]
(iii) Antinociceptive [81, 83, 84, 273, 274]
(iv) Reduced cold allodynia [83, 272]
Bio-engineered—AtT-20/hENK [84, 273]
Encapsulated Neuro2A/POMC [86]





(i) Increased ACTH release with TET-ON stimulation [86]
(ii) Reduced Phase II formalin-induced responses [75]
large T temperature-sensitive antigen (tsTag) oncogene [91].
Immortalization with tsTag can result in cell lines capable of
undergoing proliferation at permissive temperature (33◦C)
and diﬀerentiation under appropriate temperature condi-
tions (nonpermissive; 39◦C) [92, 93]. Infection of precursors
with the temperature-sensitive allele of Tag (tsTag) in vitro
[94]a n din vivo [95] has allowed cells to undergo growth
arrest and continue diﬀerentiation under nonpermissive
temperature (39◦C) conditions. These diﬀerentiating tem-
peratures are possible both in vitro, allowing transformed
c e l l st or e v e r tt oan e a r - n o r m a lp r i m a r yc e l lp h e n o t y p e ,a s
well as in vivo, where CNS transplant temperatures are near
39◦C[ 96], and tumors are not formed because the immor-
talizing gene is not expressed. Thus, conditional immortal-
ization with the oncogenic tsTag construct incorporates the
advantagesofcelllines,includingtheconvenienceofgrowing
large quantities that can be characterized and safety tested
and the ability to also genetically engineer-in the expression
of additional therapeutic molecules, while reducing the
disadvantages of tumor cell lines.
Though describing engineered-cell grafts as “biological
minipumps” for secretion of neurotrophic or antinocicep-
tive agents has only been recently discussed [97, 98], the
practicality has been examined for at least the last 25 years
[99, 100]. But, the same strategy, using engineered cells that
might secrete potentially antinociceptive molecules when
placed in the lumbar subarachnoid space after PNS or CNS
injury, much like the primary adrenal chromaﬃn cells and
opioid cell lines described above, has seen few applications
for use in chronic pain [81, 84]. But the potential application
of such cell line grafts for the diverse problems with neuro-
pathic pain in human therapy is signiﬁcant [101], given the
paucity of homogeneous primary tissue. Unlike primary or
immortalized chromaﬃn cells, the engineered cells being
tested in a variety of models of acute and chronic pain
were initially neuronal epithelial precursor cell lines derived
from the rat medullary raphe. Two lines that have been
bioengineered, called RN46A, and RN33B were isolated
from embryonic day 12.5 (E12.5) rat brainstem after immo-
rtalization with the SV40 tsTag sequence [102, 103].
Although they were derived from the same primary cultured
neuronal precursors, there are signiﬁcant diﬀerences in their
phenotypes: RN46A cells are an early serotonergic precursor
neuronalcellline,withthepotentialtoswitchdevelopmental
phenotype [102], depending on the timing and exposure
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BDNF [104], CNTF [105], GDNF [106], and ACTH [107].
This cell line was made to synthesize and secrete the neuro-
trophin BDNF, by the addition of the sequence for rat BDNF
to its genome, causing the cells to have improved survival
in vitro and in vivo, and develop a permanent serotonergic
(5HT) phenotype [108]. Since additional 5HT might be pos-
tulated to have a beneﬁcial antinociceptive eﬀect on neuro-
pathic pain [109]d i ﬀerentiated cells were placed in a lumbar
subarachnoid location after sciatic nerve chronic constric-
tion injury (CCI). Transplants of this serotonergic cell line
46A-B14, placed two weeks after CCI and the development
of severe hypersensitivity to thermal and tactile stimuli were
able to potently and permanently reverse the symptoms of
neuropathic pain [110], compared to grafts of the same cells
which did not receive the BDNF gene and did not syn-
thesize 5HT in vitro or in vivo. Transplants of other cell
lines genetically engineered to synthesize and secrete poten-
tially antinociceptive molecules such the inhibitory peptide
galanin [111], the neurotrophin BDNF [112], and the inhi-
bitory neurotransmitter GABA [113]h a v ea l lb e e nt e s t e d
after CCI and the induction of neuropathic pain, and each
has reversed the thermal and tactile allodynia and hyper-
algesia that develop after CCI. Each engineered cell line is
characterized for its particular gene expression under per-
missiveandnonpermissivetemperatureconditions,sincethe
cell lines are usually transplanted immediately after prolif-
eration at 33◦C. Following placement of the diﬀerentiating
cells in the subarachnoid space, especially in models of
pain, both cell graft survival and continued expression of
the antinociceptive phenotype were examined in vivo.A n
example of such an engineered rat neuronal cell line, the
RN33-GAD67, which synthesizes and secretes GABA after
diﬀerentiationinvitroandtransplantinvivo[113]intheCCI
pain model, where GABA is synthesized after diﬀerentiation
in these cells. But such an eﬀect for neuropathic pain seems
to require an early transplant time, since grafts of these rat
neuronal GABA cells are less eﬀective when placed late after
nerve injury [114]. With both types of behavioral hyper-
sensitivity,thermalandtactilehyperalgesia,ratGAD67grafts
causeimmediatereversalofhypersensitivitywhenthebehav-
iors are measured one week later. Such potent reversal is
common to each of the engineered cell lines used for therapy
after partial nerve injury models, and more recently with
SCI models [115–118], especially thermal hyperalgesia. But
using the CCI model of neuropathic pain and near-identical
transplantnumbersandexperimentalconditionsforallthese
studies has identiﬁed the rat GABA- and 5HT-cell lines as
especially eﬃcacious, since attenuation of hypersensitivity
is more potent and permanent in the presence of these
graft phenotypes, although early transplant time seems to be
favored in the CCI model [119]. But other antinociceptive
cell types have also been conditionally-immortalized to test
their usefulness in eventual clinical applications.
Mitotic cells found in embryonic medullary adrenal
tissue can also be conditionally immortalized with the tsTag
oncogene so that the diﬀerentiated cell type keeps many
of the phenotypic features of primary chromaﬃn cells.
Conferring immortalization with the SV40 large T antigen
expression has a variety of eﬀects on cells when the wild-type
large T protein is present, including binding of large T and
inactivation of the growth suppressors pRB, p53, and SEN6
[120, 121], a decrease in G1 and increase in G2 and M cell
cycle phase duration [122], and the ability of large T antigen
to block the diﬀerentiation process [123]. However, after
immortalization with the temperature-sensitive allele tsTag
[94, 124], immortalized cells resume the stage of life span
and function of an uninfected cell when they are shifted to
nonpermissive temperature conditions [125]. These cells at
the nonpermissive temperature have lost the ability to drive
cell proliferation, since the large T antigen is labile at the
higher temperature conditions [126] and the T antigen is not
abletodrivemitosisincellsimmortalizedwiththeconstruct,
anddiﬀerentiationisfavored[94,124].Ingeneral,SV40large
T antigen-immortalized celllines retain the phenotype of the
diﬀerentiated lineage of the parent. Cell lines generated with
the SV40 large T antigen retain contact inhibition in vitro
[127, 128] and do not produce tumors or induce immune
rejection even when injected into nude mice [129]o rr a t s
[130–137].
Rat and bovine chromaﬃn cells immortalized with tsTag
in vitro [138] express many of the markers found in primary
chromaﬃncellsandwhendiﬀerentiatedinvitro,astheonco-
genic Tag protein is degraded and mitosis ceases, these mark-
ersremainandareabletoberegulatedbycontinueddiﬀeren-
tiation, by agents such as dexamethasone and by stimulation
of the cAMP pathway with forskolin, mechanisms seen in
primarychromaﬃncells[138].Suchimmortalizedchromaf-
ﬁn cells are stable and appear homogeneous, suggesting that
they could be useful for further genetic manipulation and as
a source for transplant studies in vivo [139].
The cell biology and developmental responsiveness dur-
ing diﬀerentiation of chromaﬃn cells [140] reveals clues to
the diﬀerentiation program of conditionally immortalized
chromaﬃn cell lines in vitro. The enzyme tyrosine hydrox-
ylase (TH; EC1.14.3.x) catalyzes the rate-limiting step [141]
in the biosynthesis of catecholamines in chromaﬃnc e l l s
in the adrenal medulla [142, 143] and has been used as
one of the antigenic markers for the mature chromaﬃn
phenotype of primary rat and bovine chromaﬃnc e l l sin
vitro [144], as well as DβH and PNMT. Both the rat RAD5.2
and bovine BADA.20 chromaﬃn cell lines express these cat-
echolamine enzyme immunoreactivities at both permissive
(low levels) and nonpermissive temperatures, when the cells
areproliferating or diﬀerentiating, respectively, though levels
of the DβH enzyme appears to change with diﬀerentiation
at nonpermissive temperature (39◦C). Tyrosine hydroxylase
(TH) expression is not upregulated in the rat chromaﬃn
cell line but seems to be a feature of immortalized bovine
chromaﬃnc e l lin vitro [138]. But further increased cate-
cholamine enzyme expression in the chromaﬃn cell lines
requires treatment with forskolin and/or dexamethasone
during diﬀerentiation, since diﬀerentiation at 39◦Ci si n
serum-free medium [138]. Diﬀerentiated primary chromaf-
ﬁn cells from rat [145, 146] and bovine [34]s o u r c e sh a v e
often been used to study the synthesis and release of the
catecholamineneurotransmittersnorepinephrineandepine-
phrine in vitro. However, even with upregulation of enzyme
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and bovine cells do not synthesize catecholamines under
in vitro conditions [138]. Since chromaﬃn cell lines pro-
bably require an adequate substrate interaction for a com-
pletely normalized chromaﬃn phenotype, the absence of
detectible catecholamine synthesis in diﬀerentiated RAD5.2
and BADA.20 cells may be due to removal from their ﬁbro-
blast environment. Another possible, and more likely, expla-
nation for the absence of catecholamine synthesis is a con-
tinued low level of Tag expression, even though it is greatly
reduced after three weeks of diﬀerentiation at 39◦C. It is
possible that even a low level of Tag suppresses some normal
cellular functions, such as neurotransmitter synthesis.
This attempt at conditional immortalization of chromaf-
ﬁn cells using the tsTag oncogene and retroviral infection
in vitro, demonstrating continual cell lines retaining many
features of the mature chromaﬃn cell phenotype. The
availability of conditionally immortalized chromaﬃnc e l l
lines for a variety of studies, including their use as trans-
plants in various models of neuropathic [139], reﬂects the
growing interest in the development of molecular biological
techniques of cellular therapy for treating neuropathic pain,
but further attempts to develop the immortalization tech-
nologies were needed.
8.3. Reversible Immortalization to Create Cell Lines. The abil-
ity to reverse immortalization in a tightly controlled manner
was the logical next step in the creation of cell lines from
rare phenotypes [147] .B u ts u c hr e v e r s i b l e - i m m o r t a l i z e d
cell lines that might be used for antinociception have been
little studied [148]. The generation of chromaﬃn cell lines,
utilizing the temperaturesensitive allele of SV40 large T
antigen (tsTag) are able to reverse neuropathic pain after
transplant in the spinal subarachnoid space after CCI of the
sciatic nerve [139]. Even with near 100% disappearance of
Tag in the grafts within a few weeks after transplant [139],
oncogene expression in vivo remains a potential possibility
and such cells would not be an appropriate strategy for safe
clinical use in humans.
Studies exploiting sitespeciﬁc DNA recombination and
Cre/lox excision have suggested that cells can be targeted in
vitro[149]andinvivo[150]forremovalofdeleteriousgenes,
including the Tag sequence [151]. Reversible immortaliza-
tion with Tag and Cre/lox technology was ﬁrst reported with
human ﬁbroblasts by Westerman and Leboulch [152]a n d
more recently with human myogenic cells and hepatocytes
[153] and hepatic progenitors [154]. In these latter studies,
Cre was introduced by transfection or infection, ineﬃcient
methods that may lead to a lack of disimmortalization and
the loss, through the subsequent selection of disimmortal-
ized cells, of a signiﬁcant part of the population. Moreover,
in vivo excision is not possible. Use of a vector that allows a
silent, but inducible, form of Cre is preferred for the timed
excision of the oncogene.
A number of chimeric Cre-containing fusion proteins,
especiallyfusionswiththeligand-binding domains ofsteroid
receptors, have been created to utilize the binding by syn-
thetic ligands to activate Cre [155]. CrePR1 is a fusion pro-
tein [156], consisting of the fusion of Cre and the ligand
binding domain of a mutant human progesterone receptor
(hPRB891). Cre activity in the cells is activated by the bind-
ing of the steroid RU486, which in turn induces the trans-
location of CrePR1 to the nucleus where the Cre is active
to excise the ﬂoxed sequences. The requirement for RU486
and the use of a mutated steroid receptor for disimmor-
talization would assure that if nondisimmortalized cells
were transplanted, Cre would not be activated by circulat-
ing endogenous progesterone, a strategy used for inducible
recombination with in vivo CNS studies [157].
It has been demonstrated [158] that embryonic rat
adrenal chromaﬃn cells could be immortalized with a onco-
genic tsTag construct, utilizing retroviral infection of these
early chromaﬃn precursors, where the tsTag construct (tsA-
TN) was ﬂanked by loxP sequences. Following isolation of
immortalized cells using positive neomycin selection, the
cells were further infected with a retrovirus expressing the
CrePR1 gene, which encodes a fusion protein which com-
bines Cre activity plus the mutant human steroid receptor,
hPRB891. Cultures of embryonic rat adrenal cells were
immortalized with the tsA-TN retroviral vector encoding
the loxP-ﬂanked temperature-sensitive allele of SV40 large
T antigen (tsA-TN), which included a positive/negative
neo/HSV-TKsequenceforselectionwitheitherG418organ-
cyclovir, respectively.
A number of chimeric Cre-containing fusion proteins,
especiallyfusionswiththeligand-binding domains ofsteroid
receptors, have been created to utilize the binding by syn-
thetic ligands to activate Cre [155]. CrePR1 is a fusion
protein [156], consisting of the fusion of Cre and the ligand
binding domain of a mutant human progesterone receptor
(hPRB891).
When immortalized chromaﬃn cells are disimmortal-
ized with cre-lox technology to disimmortalize the chromaf-
ﬁn cells in vitro, complete removal of the Tag sequence
before diﬀerentiation seems to allow neurotransmitter syn-
thesis and a more normal phenotype [158]. Compared to
downregulation of the tsTag protein in conditionally immo-
rtalized rat chromaﬃn cells, disimmortalization in vitro
in these disimmortalizable rat chromaﬃn cells, called the
loxtsTag/CrePR1/RAD chromaﬃn cell line, the Tag protein
was completely and eﬃciently removed by 10 days of treat-
mentwithRU486,followedbyincubationwiththeantibiotic
gancyclovir [158]. Cells which were not disimmortalized,
wereremovedbytheircontinuedexpressionofthethymidine
kinase (TK), which is toxic in the presence of gancyclovir
[159].
Irreversible removal of a potentially subverting oncogene
by its excision using the Cre/Lox system might thus be a clin-
ically useful strategy, especially since the core temperature
of humans is lower than that of rodents, and the expression
of a temperature-sensitive antigen might not be completely
blocked in a clinical context [152, 160–164]. Note that in this
respect, use of moduletable Cre activity that can be activated
by the synthetic steroid RU486 [156, 157] has added a means
to select the timing of disimmortalization and render the
overall procedure more ﬂexible and eﬃcient. Interestingly,
the disimmortalized rat chromaﬃn cells had very increased
expression of tyrosine hydroxylase (TH), the rate limiting
enzyme for catecholamine synthesis, in vitro.T h i sw a sPain Research and Treatment 9
Table 3: Strategies for creating cell lines.
Source Model Results Antinocicptive Molecule
Released
Conditionally immortalized Cell lines:
Embryonic rat Raphe/SV40tsTag
[102, 103, 275–277]
Embryonic rat DRG neuron, 50B11
[90]
Human DRG neuron, HD10.6,
v-myc [278]






(i) Expressed capsaicin receptor transient
receptor potential vanilloid family-1
(TRPV-1) and responded to capsaicin in
vitro [90]
(ii) Expressed sensory neuron-associated
transcription factors and exhibited capsaicin
sensitivity [278]
(iii) Antinociceptive [139]















[84, 110, 113, 116, 119, 158, 211]
(ii) Restores dorsal horn GAD/GABA system
in CCI [229]
(iii) Only intrathecal, not intraspinal, grafts
of 5HT cells are antinociceptive [115]
(iv) Attenuates bilateral DH hypersensitivity
[117]
(v) Restores spinal serotonin, downregulates
the serotonin transporter, and increases
BDNF tissue content [118]
(vi) Reduce formalin-evoked c-fos
expression [170]
(i) 5HT
[110, 116–118, 211, 229]
(ii) BDNF [110, 118, 211]
(iii) GABA [110, 113]
(iv) galanin [111]
(v) Met-enkephalin [170]
Reversibly immortalized Cell Lines:
Tetracycline-regulated of SV40 large
T-antigen (Tag) in human embryonic
stem (ES) cells and mice [147]
Cre/lox-regulated Disimmortalizable
Embryonic rat chromaﬃnc e l l s[ 158]
Partial nerve injury




accompanied by 5-fold increase in norepinephrine synthesis
in vitro [158]. But these disimmortalizable rat chromaﬃn
cells not only synthesize epinephrine after Tag excision, but
they also apparently make increased catecholamine enzymes
besides TH, judged by qualitative immunohistochemistry
for the enzymes compared to both nonexcised and those
immortalized with only tsTag [138]. Also of importance,
transplant of disimmortalized rat chromaﬃn cells was able
nearlyeliminateneuropathicpainintheCCImodelofpartial
nerve injury, when compared to the injury alone or trans-
plant of immortalized chromaﬃn cells. Rather than sug-
gesting that antinociception is the result of catecholamine
synthesis, release or secretion from grafted chromaﬃn cells,
the existence of an equivalent functional eﬀect by nondisim-
mortalized cells suggests that another agent or mechanism is
responsibleforreductionofneuropathicpainbythesegenet-
ically manipulated chromaﬃn cells, at least in this model of
pain. Even if chromaﬃn grafts do not make signiﬁcant levels
of catecholamines in vivo, the antinociception the grafts
provide might be a result of other antinociceptive molecules
synthesized and released by the cells, such as GABA or
met-enkephalin. Presumably the increased norepinephrine
phenotype recovered following excision of the oncogene by
disimmortalized cells would function to advantage in cell
therapy, but with disimmortalized rat chromaﬃnc e l lg r a f t s
no such advantageous eﬀect could be demonstrated. Rather,
the value of disimmortalization before transplantation is to
provide a measure of safety, with the complete absence of the
oncogene and prevention of even a remote possibility of viral
transfer of the large T antigen in the host, after grafting such
cells (Table 3).
8.4. Transgenic Opioid Expression in Immortalized Cell Lines.
A further advance to model genetically modiﬁed, disimmor-
talizable chromaﬃn cell lines, is the work by Duplan
and colleagues [165], who infected the disimmortalizable
loxtsTag/CrePR1/RAD chromaﬃn cell line with constructs
for the synthesis and secretion of the opioid met-enkephalin
(met-Enk). These transgenic rat chromaﬃn cell lines expres-
sed easily detectible met-ENK in vitro cells, which contained
the met-ENK construct contained high levels of this opioid.
The transgene also contained a neurotrophin growth factor
(NGF) sequence for secretion of synthesized nascent protein,
and chromaﬃn cells which contained the met-ENK trans-
gene were able to secrete the highest levels of the met-ENK
opioid from the cells. The value of opioids from chromaﬃn
grafts in cellular therapy, especially for pain [166], has seen
precedents in both animal [32, 62, 167], and more recently,10 Pain Research and Treatment
human clinical work [43, 71, 165] when primary chromaﬃn
tissue was used as a graft source. When these disimmortal-
izable loxtsTag/CrePR1/RAD chromaﬃnc e l l sw e r eg r a f t e d ,
by Duplan and colleagues, two weeks before injection of
formalin into the hindpaw in a model of tonic pain [168,
169], those rats which had been given grafts of cells which
secreted met-ENK did not develop the long-term response
to formalin injection, compared to rats which had no
grafted cells or those that had only received cells which were
transgenic for the vector only [170]. Although it is not yet
known how disimmortalization may inﬂuence the expres-
sion of transgene, such as the opioid met-ENK gene used
here, irreversible removal of a potentially subverting onco-
gene by its excision using the cre/lox system might be a clin-
ically useful strategy. Of course, immortalization of human
chromaﬃn tissue with an oncogene, such as SV40Tag,
is not likely with any potential for deleterious expres-
sion of SV40 proteins [171], but disimmortalization utilizing
cre/lox site-directed removal of oncogenes in a growing
technology to create useful graft sources for cell therapy for
a variety of conditions [160, 161, 172]. There are a variety
of possible oncogenic sequences that could be used for the
reversible immortalization of human chromaﬃn cell lines,
including v-myc [173]. However, the creation of reversibly
immortalizable human chromaﬃn cell lines, perhaps from
precursors [174], is still somewhat in the near future [175].
But such a homogeneous source will also allow for the
manipulation of the chromaﬃnc e l l ’ sg e n o m et oi n v e s t i g a t e
the mechanisms of action responsible for cell grafts to repair
the injured CNS environment. Similar immortalization of
human chromaﬃn precursors and creation of human chro-
maﬃnlines[65,67,73]presagetheadventofcellulartherapy
as a therapeutic strategy that includes further development
of human stem cell and progenitor/precursor cell lines
[176].
9. CurrentStrategies for Immortalized
CellLines: Rationale/Studies
9.1. Stem Cells. An increasing number of articles describing
regenerativemethods toimprove functionafterinjury andin
certaindiseasestateshaveappearedinthelastfewyears.Most
are related to transplants with stem cells [98], progenitors
[176, 177], and bone marrow and nontransplants. Stem
cell transplants can be ranked in the following descending
order of preference; bone marrow-derived cells, neural stem
cells, human umbilical cord blood cells, embryonic stem
cells, and myoblasts. Bone-marrow-derived cells and human
umbilical cord blood cell have been used for study in various
disease ﬁelds. The nonstem cell transplantation group is
made up primarily of islet cells, followed by biomaterials,
and other cells or tissues from a variety of sources [178].
With their more limited multipotency, the use and potential
of progenitor cells for improving function has still made
signiﬁcant progress recently [179–181], especially in the
potential for renal and cardiac regeneration and reduction
of ischemia [181–183]. But another critical potential to be
fulﬁlled is in the area of the management of chronic, and
especially neuropathic, pain.
9.2. Stem/Progenitor/Precursors (Animal Studies). In a recent
report [184] utilizing the partial nerve injury with CCI to
induce neuropathic pain, rat spinal embryonic progenitor
cells (SPC) that used basic ﬁbroblast growth factorB2
(FGF-2) for proliferation of the SPC in vitro were able
to reduce thermal hyperalgesia after intrathecal transplant.
Presumably, grafted cells had been induced to a GABAergic
phenotype by FGF-2 in vitro and survived in its absence
after transplant, maintaining their phenotype to modulate
the neuropathic pain. The authors suggest that the grafts
also increased the glycine content in the CSF of grafted
animals, suggesting that if precursors could be induced
to a phenotype that provides nociceptive inhibition, they
would function much like cell minipumps, surviving in
the intrathecal space. Also in the CCI model of peripheral
pain, freshly isolated syngeneic marrow mononuclear cells
were injected i.v. following the unilateral nerve injury and
tactile allodynia and thermal hyperalgesia evaluated weekly.
Marrow transplantation did not prevent pain, and 5 days
after CCI all animals were equivalently lesioned. However, 10
daysafterCCI,ratsthatreceivedmarrowtransplantsdemon-
stratedpawwithdrawalresponseandpawwithdrawallatency
patterns indicating recovery from pain, whereas untreated
rats continued to have signiﬁcant pain behavior patterns.
The mechanisms underlying this improvement following
bone marrow injection are unknown. The authors speculate
that the marrow cells functioned as anti-inﬂammatory,
neuroprotective, and proangiogenic, modulating ischemic,
inﬂammatory, and cytotoxic events in the pain that follows
nerve constriction in this model. However, marrow trans-
plants are also known to exacerbate diabetic neuropathy in a
diﬀerentmodelofpain[185].Inthiscase,marrowcellsfused
with peripheral neurons, stimulating apoptosis.
One cause of severe neuropathic pain is traumatic injury
that involves SCI is spinal root avulsion, and replacement
of DRG neurons could reduce that pain. A recent study
investigated whether human neural stem/progenitor cells
(hNSPCs) transplanted to the DRG cavity can serve as
a source for repairing lost peripheral sensory connections
[186] .T h eh N S P C sr o b u s t l yd i ﬀerentiate to neurons, which
survive long-term transplantation. The neuronal population
in the transplants was tightly surrounded by astrocytes,
suggesting their active role in neuron survival. Furthermore,
3 months after grafting, hNSPCs were found in the dorsal
root transitional zone (DRTZ) and within the spinal cord.
The level of diﬀerentiation of transplanted cells was high
in the core of the transplants whereas cells that migrated
to the DRTZ and spinal cord were undiﬀerentiated, nestin-
expressing precursors. However, hNSPCs are not suﬃcient
to restore normal sensory function; additional factors are
required to guide their diﬀerentiation to the desired type of
neurons.
9.3. Neuroprogenitor Cell Lines for Pain (The NT2 Cell
Line). More than two decades ago, it was discovered that,
when treated with retinoic acid (RA), a human embryonal
carcinomacellline,NTera2cl.D/l(NT2,hNT2),diﬀerentiates
irreversibly into several morphologically and phenotypically
distinct cell types, which include terminally diﬀerentiatedPain Research and Treatment 11
postmitotic CNS neurons [187, 188]. Successive replating of
RA-treated NT2 cells, in the presence of growth inhibitors,
results in the isolation of puriﬁed human neurons [189],
which have been extensively characterized and tested in vivo
in a number of animal models of traumatic injury and
neurodegenerative disease [188, 190–194]. This NT2 human
neural cell line has been used for a variety of studies that
reveal not only the regulation of an oncogenic phenotype by
agents such as retinoic acid [189, 195, 196], but it has been
well characterized for the expression of a variety of neural
phenotypic properties [197] and proteins [198, 199]w i t h
diﬀerentiation of the cells in vitro and in vivo [200]. The
potential application of NT2 neurons in cell transplantation
therapy for CNS disorders, and their use as vehicles for deliv-
eringexogenousproteinsintothehumanbrainforgenether-
apy, has been envisioned [201]. Such NT2 neurons have been
used in Phase I-II clinical trials for the treatment of stroke
[202–204], and this cell line or its derivatives can likely be
utilizedforfurtherreparativetransplantstrategies[205].The
rate-limiting enzyme GAD, for GABA synthesis is present in
diﬀerentiating NT2 neurons in vitro [206, 207], and GABA
is a phenotype for NT2 cells diﬀerentiated and transplanted
in vivo [208]. But the NT2 cell line has a great variety of
phenotypes expressed in diﬀerentiated cells [193, 207], mak-
ing it less-than-ideal for a speciﬁc antinociceptive phenotype
expression that might be required for application in pain
management, as has been modeled in rat cell lines described
above. While induction of a GABAergic phenotype in neural
stem cells is possible with a somewhat complicated method
of sequential exposure toepigenetic signals in vitro [209],the
host graft environment does not always allow for induction
of desirable phenotypes in vivo [210]. A naturally occurring,
stableantinociceptivephenotypeinaclinicallyusefulhuman
progenitor cell line, such as that derived from the NT2 cell
line, is more desirable, and these are described below.
9.4. NT2-Derived Cell Lines for Pain. Since the NT2 cell line
contains a mixed phenotype population of cells, many of
which would likely be antinociceptive based on multiple
studies with rat cell lines by this author and others using
central and peripheral models of neuropathic pain [110, 111,
113, 115–119, 170, 211], it was considered likely that indi-
vidual cell lines could be subcloned from the NT2 parental
cell lines, using ordinary subcloning techniques involving
isolation of individual cells plated sparsely, allowing them
to grow into colonies, surrounding these with cloning rings,
and removing these colonies to establish individual cell
lines. This rather laborious process resulted in a number of
well-growing, morphologically and immunohistochemically
distinct NT2 subclonal cell lines, numbered consecutively as
they were isolated. Two of the cell lines were chosen for their
potential to function as sources of neurotransmitters which
might prove useful in further testing in animal models of
pain, the hNT2.17 [212]a n dh N T 2 . 1 9[ 213] cell lines. Since
they are derived from the neuroprogenitor parent cell line
NT2, these are considered to be human neuroprogenitor cell
lines as well, resulting in a neuronal-limited phenotype, and
will be described below. These human progenitor cell lines
are being developed for clinical use. Their characterization
and use in animal models reﬂect what will be required of any
similar regenerative cell therapy for FDA approval [98, 214].
9.5. The Human Neuronal GABA hNT2.17 Cell Line. Cen-
trally induced excitotoxic SCI has been developed as a model
of neuropathic pain [215, 216]. Intraspinal injection of
quisqualic acid (QUIS), a mixed AMPA/metabotropic recep-
tor agonist, produces injury with pathological characteristics
similar to those associated with ischemic and traumatic
SCI [217]. In addition, the pathological changes that this
SCI induces, signiﬁcant mechanical allodynia, and thermal
hyperalgesia have been shown to be important behavioral
components, without the additional motor dysfunction seen
in other SCI models [218]. Each of these sensory behaviors is
indicative of altered sensory function and/or pain, similar to
that reported after SCI. After spinal transplantation of pri-
mary adrenal tissue grafts following QUIS injections, pain-
related behaviors, including the hypersensitivity to mechan-
ical stimuli and “excessive grooming” were signiﬁcantly
reduced[219].GiventherelatedlossofGABAinhibitionthat
seems to accompany SCI and the induction of neuropathic
pain[220–222], the excitotoxic SCI model was used to exam-
ine the hNT2-derived GABAergic hNT2.17 cell transplant
into the lumbar subarachnoid space following injury and the
ability of those grafts to reverse behavioral hypersensitivity
[212]. These cells cease to express tumor genes, express an
exclusively neuronal, GABAergic and glycinergic phenotype,
and synthesize, secrete and release GABA and glycine into
the extracellular environment with diﬀerentiation [212].
Their morphology is similar to the GABA/glycine spinal
interneurons found in the dorsal horn sensory laminae [223]
and such characteristics are stable in more than 10 years of
use in transplant studies. These inhibitory human neurons
additionally co-localize GABA and glycine and the vesicular
inhibitoryaminoacidtransporter(VIATT,VGAT),especially
along the neurite outgrowths in vitro, suggesting that this
molecular machinery allows co-release in hNT2.17 cells
[224], without the need for a separate glycine transporter.
When diﬀerentiated hNT2.17 cells are placed two weeks after
the QUIS SCI, mechanical allodynia and thermal hyperalge-
sia are potently and permanently attenuated, with no greater
eﬀect when twice the normal transplant dose (1 million
cells/i.t. injection) is used [225, 226], or grafts are placed
in the cervical subdural space [226]. Besides transplant dose
and graft placement, the immunosuppression regimen and
transplant time after SCI were also optimized [226]. The
same optimal transplant dose was only moderately eﬀective
whenplacedinchronic SCI, sixweeksafterSCI, comparedto
100%eﬀectivenesswhenplacedinanacuteSCI,2weeksafter
injury.Additionally,maximalgrafteﬀectivenessrequiredtwo
weeks of immunosuppression with cyclosporine A (CsA;
10mg/Kg), immediately following transplant. No immuno-
suppression or less lengthy exposure to CsA provided
minimal or no attenuation [226]. The “excessive grooming”
behaviors associated with this model were also examined.
When excessively grooming rats that had been transplanted
with either viable or nonviable hNT2.17 cells and exposed
to diﬀerent immunosuppression regimens were examined
for development, resolution, worsening, or no change of12 Pain Research and Treatment
excessive grooming, a trend toward improvement was asso-
ciated with viable grafts and at least 1 week of accompanying
CsA immunosuppression. When transplant was delayed to 6
weeks,noimprovementinexcessivegroomingwasseen.This
last ﬁnding duplicates what was seen in the QUIS SCI model
and graft of antinociceptive adrenal medullary tissue [219],
suggesting potent reversal of behavioral hypersensitivity
may have a neuroprotective eﬀect on the progression of
spinal excitotoxicity associated spinal lesions. We [227], and
others [228], have recently reported on the use of hNT2.17
cell therapy in various other models of peripheral and
central nervous system damage, including: CCI of the sciatic
nerve, streptozotocin-induced diabetic peripheral neuropa-
thy (DPN) pain, and severe contusive SCI. Much as we [229]
and others [56] have seen in the CCI peripheral nerve injury
model and antinociceptive cell grafts Vaysse and colleagues
[228], reported that the decrease in GABA expression in the
spinal dorsal horn of CCI injured animals is concomitant
with a decline of its synthetic enzyme GAD67 immunore-
activity (ir) and mRNA but not GAD65. In hNT2.17 trans-
planted animals a strong induction of GAD67 mRNA one
week after graft was seen, which was followed by a recovery
of GAD67 and GABA ir. This eﬀect paralleled a reduction of
hindpaw hypersensitivity and thermal hyperalgesia induced
by CCI. These results suggest not only that hNT2.17 GABA
cellscanmodulateneuropathicpainafterCCIbyminimizing
the imbalance and restoring the cellular GABAergic pathway,
butthatsuchamechanismmaybeassociatedwithanypotent
antinociceptive cell graft, at least in the CCI model. The
same, or a similar mechanism may explain the antinocicep-
tive eﬀects of hNT2.17 grafts in contusive SCI and DPN pain
[227]. DPN pain studies have suggested aberrant spinal or
supraspinal modulation of sensory processing [230, 231],
including a central mechanism [232] with the ventral pos-
terolateralthalamusbecominghyperexcitableinthepresence
of spinal and supraspinal disinhibition. Disinhibition and
loss of spinal GABA modulation are also well reported in
SCI pain [222]. But evidence for a GABAergic mechanism
associated with hNT2.17 transplant and antinociception in
these other models of pain awaits further studies.
9.6. The Human Neuronal 5HT hNT2.19 Cell Line. Current
understanding of central and supraspinal [233] mechanisms
for the induction and maintenance of chronic pain after SCI
suggests a major role for the hypofunction of serotonergic
(5HT) inhibitory systems [234–236]. This same SCI leads to
the loss of descending serotonergic excitatory inputs caudal
to the lesion site and altered neurotransmitter status within
the ventral horn a-motoneurons, which also contributes to
motor dysfunction after SCI [116, 237]. A variety of animal
studies have used a 5HT rat cell line [110, 116–118]o r
5HT raphe transplants [238, 239]a sam e a n st oa m e l i o r a t e
some of these problems. Supplemental cell therapy can also
work to create a spinal environment to ameliorate local
damage and simultaneously promote a regenerative response
in multiple axonal populations, including descending spinal
serotonin ﬁbers [240], or reverse chronic pain after SCI by
reversing the hyperexcitability in the dorsal horn pain pro-
cessing centers [117]. We have described the use of 5HT cell
therapy with a rat 5HT cell line that is able to permanently
reverse neuropathic pain that develops after partial nerve
injury [110] and hemisection SCI [115, 241]. The human
neuronal5HThNT2.19cellsusedforcelltherapyaftersevere
contusive SCI reverses behavioral hypersensitivity [241],
without aﬀecting motor dysfunction when grafts are placed
intrathecally. These same cell grafts modestly recover motor
function when placed intraspinally [213] in the same severe
contusionSCImodelofchronicpainandmotordysfunction.
Additionally, grafts of hNT2.19 cells attenuate tactile allo-
dynia and thermal hyperalgesia in the excitotoxic SCI QUIS
model [227], much like grafts of hNT2.17 cells. In fact, lum-
bar intrathecal 5HT hNT2.19 and GABA hNT2.19 grafts are
equally nociceptive no matter which SCI pain model is used,
excitotoxic or contusive [227], suggesting that these cells
may aﬀect the same or similar mechanism-of-action that is
common to both models that initiates behavioral hypersen-
sitivity. We have already shown a GABAergic mechanism-
of-action for grafts of hNT2.17 cells [228]a n ds u g g e s t e di t
may be common in SCI pain. Although grafts of a 5HT rat
neuronal cell line which is antinociceptive after hemisection
SCI [116], depending on graft location [115], much like
grafts of hNT2.19 cells, it does so by attenuating bilateral
hyperexcitability of dorsal horn neurons [117], restores
spinal serotonin, downregulates the serotonin transporter,
and increases BDNF tissue content in the spinal cord [118],
these same 5HT rat cell line grafts also induce a GABAergic
mechanism of action in the CCI model of nerve injury
and neuropathic pain [229]. Obviously, it will be important
in future studies to understand how each separate human
neuronal cell line provides antinociception in each PNS or
CNS pain model, but the same or similar mechanisms are
not out of the question. Since the 5HT hNT2.19 cells, like
the hNT2.17 cell line, are exclusively neuronal, although
with a diﬀerent neurotransmitter phenotype, and equally
nontumorogenic before and after transplant [227, 241], this
human progenitor cell line is equally appropriate to develop
as a clinical tool, not only to treat neuropathic pain, but also
motor dysfunction, especially after SCI [241–243]( Table 4).
10. Summary of Advantages and
DisadvantagesandFutureDirectionsof
Cell-Therapy Approaches
To summarize the conclusions from 30 years of cell therapy
studies, the advantages and disadvantages of a cell-based
approachtothetreatmentofneuropathicpainwouldinclude
the following (1) It is likely that only human cells will be use-
ful as a source, whether primary tissue or cell lines given that
suchsourcesaretheleastlikelytoberejected,wouldfunction
appropriately, and respond to environmental cues in the
human host. Encapsulation technologies could be helpful
here, if these technologies could keep the grafts both viable
and functional. However, (2) it is likely that there are limits
to the achievable levels of a given biologic agent that can be
delivered by the cells and multiple intrathecal injections over
time, with return of pain, may be necessary. (3) It is possible
that delivery of a multitude of substances, in addition toPain Research and Treatment 13
Table 4: Stem/Precursor cell lines.
Source Model Results
Stem/Progenitors:
Rat spinal (embryonic) progenitor cells
[184]
Adrenal progenitors—human [281]
Partial nerve injury (CCI) [184] (i) Reduced thermal hyperalgesia [184]
Human neuronal/progenitors:
Human NT2 cell line [205, 282, 283] Excitotoxic SCI pain [283] (i) Release cannabinoids [282]
(ii) Antinociceptive [283]
Human NT2.17 GABA cell line
[212, 225, 226, 228, 283, 284]
Excitotoxic SCI (QUIS)
[212, 225, 226, 283–285]
Streptozotocin-induced diabetic
peripheral neuropathy (DPN) [283]
Partial nerve injury (CCI) [228, 283]
(i) Antinociceptive [212, 226, 228, 283]
(ii) Restores spinal GABA DH inhibition [228]
(iii) Colocalize/release GABA and glycine [212]
Human NT2.19 5HT cell line
[213, 241, 283]
(i) Contusive SCI [213, 241]
(ii) Excitotoxic SCI [283]
(i) Intraspinal grafts attenuate motor
dysfunction [213]
(ii) Intrathecal grafts provide antinociception
[241, 283]
those of therapeutic interest, many of which cannot be
completely deﬁned before hand, will be associated with cell-
based therapy. Diﬀerent subgroups of pain patients may
respond to such agents in either positive or negative ways
dependent on each person’s primary cause of pain. Valid and
reliable phenotypic classiﬁcation of pain based on individual
signsandsymptoms,andvariousbiomarkers,maybehelpful
in deﬁning such subgroups and their responses to a speciﬁc
substance related to cell transplant. Such responses are
unknown until very large populations are treated with any
given cell source. (4) It seems that more acute neuropathic
pain is treatable with cell therapy; chronic pain may require
multiple i.t. injections as needed. Even still, pain relief may
not be equally eﬀective in all cases, and additional pharma-
cologic and cognitive/adjuvant therapies will be needed. (5)
There is a dependence on the survival of implanted cells,
which may be limited by immunologic factors, nutrient and
oxygen supply, and so forth. However, such survival and
eﬃcacy can be tested preclinically, in nonhuman studies. (6)
It is likely, at least for now, that only the simplest approaches
to creating cell sources will be quickly approved for clinical
trials, that is, not overly-manipulated (in cell culture) or
bio-engineered cells (containing viral vectors). (7) Some
course of immunosuppression will likely be required, even
for autologous sources, but such regimens could be tested
rigorously in preclinical experiments, that is, nonhuman
primates. (8) An intrathecal graft site would likely be the
best for cell injections for the treatment of neuropathic pain.
Any other transplant type would need to be placed as near
to its “site-of-action” as is reasonable, especially if graft-
ed cells are known to not migrate, such as with NT2 cells. (9)
If cells are used for antinociception, and placed intrathecally,
those that passively secrete inhibitory (or drive inhibitory
systems)neurotransmitterswouldlikelyworkthebest,rather
than cells that secrete any number of known and unknown
agents. (10) Transplant sources need to be tested in as
many preclinical peripheral and central models of motor
and sensory injury as possible, to avoid later “oﬀ-label”
use/side-eﬀects in humans. (11) A pragmatic, rather than
a purely mechanistic, approach can be used for preclinical
work.Itismoreusefulthatcelltherapyapproachesaretested,
without necessarily understanding how they work, as long
as such technologies are proven as safe as possible. (12) All
eﬀorts should be taken to keep patients/provider costs as
low as possible, so that cell therapy can be applied almost
as readily as pharmacologic treatments. Cell-based research
and development will likely be an expensive and complicated
solution to treat pain, compared to a purely pharmacologic
or mixed-use mechanical-pump/spinal-stimulator delivery
approach. (13) The rapid establishment of a Research Ethics
Consortium should be established, to be tasked to assem-
ble an interdisciplinary panel of experts who will apply
ethical principles to analyze the social merit relative to the
economic incentives of this emerging technology [244]. This
consortium will evaluate how these novel ethical issues in
emergingtechnologiesareaddressedundercurrentoversight
and regulatory structures and where there may be gaps and
need for revised or new public policy approaches.
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